Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany myDRG Stellenmarkt Gesundheitswesen

« Veröffentlichung der Vergleichsdaten nach § 6 Psych-Krankenhausvergleichs-Vereinbarung | Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany | Klinische Kodierfachkraft (w/m/d) Kreis-Krankenhaus Mechernich GmbH »

 

Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany

Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany (Springer).

Drug-coated balloons (DCBs) for femoropopliteal peripheral artery disease have been shown to be clinically superior and cost-effective compared to conventional percutaneous transluminal angioplasty (PTA). However, few studies enrolled patients with...

Drug-coated balloons (DCBs) for femoropopliteal peripheral artery disease have been shown to be clinically superior and cost-effective compared to conventional percutaneous transluminal angioplasty (PTA). [...] Our objective was to study the cost-effectiveness of endovascular treatment with versus without DCB in CLTI patient populations in the Netherlands and Germany.
[...]
Conclusion Urea excipient drug-coated balloon therapy for treating CLTI from
femoropopliteal artery disease is associated with improved patient outcomes and
expected overall cost savings to payers in the Dutch and German healthcare
systems, rendering it a cost-effective and likely dominant treatment strategy.


Quelle: Springer, 04.01.2022

- - - - - - - - - -



erschienen am Dienstag, 04.01.2022